Hyrimoz is available in 40 mg pre-filled syringes and pens, containing adalimumab, a recombinant human monoclonal antibody.

Indications:

Rheumatoid Arthritis: For adults with moderate to severe RA, especially when methotrexate (MTX) or other DMARDs are insufficient.

Juvenile Idiopathic Arthritis: For children aged 2+ with active polyarticular juvenile idiopathic arthritis.

Enthesitis-related Arthritis: For patients aged 6+.

Axial Spondyloarthritis and Ankylosing Spondylitis: For adults with severe active conditions.

Psoriatic Arthritis: For adults with inadequate response to previous therapies.

Psoriasis: For adults with moderate to severe chronic plaque psoriasis.

Hidradenitis Suppurativa: For adults and adolescents from 12 years.

Crohn’s Disease: For adults and children from 6 years.

Ulcerative Colitis: For adults with moderately to severely active UC.

Uveitis: For adults and children from 2 years with non-infectious intermediate, posterior, and panuveitis.